Jesan Ataharul is an associate in the firm's capital markets and mergers & acquisitions groups. His practice focuses on transactional matters, including representing clients in connection with capital markets transactions, private financings as well as domestic and cross-border M&A transactions.

Jesan regularly advises clients on securities law reporting and compliance obligations, stock exchange rules and regulations and corporate governance matters. He further represents public and private companies in a broad range of strategic transactions, including stock and asset purchases & sales, joint ventures, technology licensing & transfer and distressed transactions.

During law school, Jesan was president of the Private Equity & Venture Capital Society and served as an editor for the University of Pennsylvania Journal of Business Law. Prior to law school, Jesan worked at the Legal Services Center of Harvard Law School and at the United States Senate for U.S. Senator John McCain of Arizona.


  • Advised TransMedics Group, Inc. in its acquisition of organ support and heart preservation transport system assets from Bridge To Life Ltd.
  • Representation of the underwriters in a $275 million registered direct offering of Insmed Incorporated's common stock.
  • Advised client with its exchange offer: stock options in exchange for restricted stock units.
  • Representation of ImmunoGen, Inc. in a multi-target license and option agreement with ImmunoBiochem Corporation.
  • Advised the underwriters in connection with a $150 million registered at-the-market offering of a commercial biotechnology company's common stock.
  • Representation of the noteholders of Quotient Limited in Chapter 11 proceedings.
  • Representation of Welvie in its sale to Paradigm.
  • Advised ImmunoGen, Inc. in its Non-Dilutive Term Loan Financing of up to $175 million with Pharmakon Advisors.
  • Representation of McAfee Corp. in its $14 billion acquisition by an investor group comprised of Advent International, Permira Advisers, Crosspoint Capital, Canada Pension Plan Investment Board, GIC and ADIA.
  • Representation of a global biotechnology company in an agreement to sell their equity stake in a joint venture for $2.3 billion.
  • Advised Ginkgo Bioworks in an agreement to acquire biotechnology company Zymergen in an all-stock transaction valued at $300 million.

Areas of Practice